TXG
NASDAQ10x Genomics Inc.
News · 26 weeks46+300%
2026-03-012026-08-23
Mix2690d
- Insider14(54%)
- SEC Filings5(19%)
- Other3(12%)
- Earnings2(8%)
- M&A1(4%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form 144 filed by 10x Genomics Inc.144 - 10x Genomics, Inc. (0001770787) (Subject)
- INSIDERChief Executive Officer Saxonov Serge gifted 4,000 shares, decreasing direct ownership by 0.36% to 1,104,380 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Teichmann Sarah A. sold $432,279 worth of shares (7,551 units at $57.25) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 28,058 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by 10x Genomics Inc.SCHEDULE 13G/A - 10x Genomics, Inc. (0001770787) (Subject)
- INSIDERDirector Stuelpnagel John R sold $1,155,055 worth of shares (20,000 units at $57.75), decreasing direct ownership by 5% to 348,436 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- SECSEC Form 144 filed by 10x Genomics Inc.144 - 10x Genomics, Inc. (0001770787) (Subject)
- SEC10x Genomics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - 10x Genomics, Inc. (0001770787) (Filer)
- PR10x Genomics Reports Second Quarter 2026 Financial ResultsPLEASANTON, Calif., Aug. 6, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today reported financial results for the second quarter ended June 30, 2026. Recent Updates Revenue was $151.0 million for the second quarter of 2026. Excluding $1.6 million related to a patent litigation settlement, revenue was $149.4 million. Revenue increased 3% over the corresponding period of 2025 when excluding non-recurring settlement revenue in both the current and prior-year periods.Acquired Proteintech Genomics, a division within Proteintech Gr
- PR10x Genomics and Lausanne University Hospital Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies for Cancer CareCollaboration aims to identify biomarkers predictive of treatment response across multiple cancer types using 10x's single cell and spatial platformsPLEASANTON, Calif., July 29, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Lausanne University Hospital (CHUV), one of Switzerland's leading academic medical centers, to advance research in diagnostic applications of single cell and spatial technologies for cancer care. This collaboration builds on 10x's broader efforts to work with le
- PR10x Genomics to Report Second Quarter 2026 Financial Results on August 6, 2026PLEASANTON, Calif., July 15, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, announced it will report financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026. The company will host a public conference call and live webcast for analysts and investors beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its results, business developments and outlook. The news release with the financial results will be accessible from the company's website prior to the conference call.
- INSIDERChief Executive Officer Saxonov Serge sold $1,033,269 worth of shares (30,000 units at $34.44) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 1,108,380 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- PRIQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief ScientistCiesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a me
- INSIDERDirector Suliman Shehnaaz sold $186,756 worth of shares (5,723 units at $32.63) as part of a pre-agreed trading plan, decreasing direct ownership by 15% to 31,722 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- PR10x Genomics and Cleveland Clinic Collaborate to Advance Research in Diagnostic Applications of Single Cell and Spatial Technologies in Patients with Bladder CancerCollaboration aims to identify biomarkers predictive of antibody-drug conjugate (ADC) treatment response using 10x's single cell and spatial platformsPLEASANTON, Calif., June 17, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced a research collaboration with Cleveland Clinic, a nonprofit multispecialty academic medical center that integrates clinical care with research and education, to advance research in novel diagnostics for bladder cancer. This collaboration is part of 10x's broader efforts to partner with lead
- SECSEC Form 144 filed by 10x Genomics Inc.144 - 10x Genomics, Inc. (0001770787) (Subject)
- PR10x Genomics Acquires Proteintech Genomics, a Division Within Proteintech GroupAcquisition Expands 10x Genomics' Capabilities in Proteomics PLEASANTON, Calif., June 9, 2026 /PRNewswire/ -- 10x Genomics, Inc. (NASDAQ:TXG), the life science technology leader focused on accelerating science and advancing human health, today announced the acquisition of Proteintech Genomics, a division within Proteintech Group, a company specializing in developing high-plex proteomic solutions for single cell and spatial applications on 10x platforms. The acquisition marks a strategic expansion of 10x's proteomics capabilities. Proteintech Genomics brings differentiated technologies, including its Human Discovery Panel, the l
- INSIDERDirector Teichmann Sarah A. was granted 8,829 shares, increasing direct ownership by 33% to 35,609 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Suliman Shehnaaz was granted 8,829 shares, increasing direct ownership by 31% to 37,445 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Stuelpnagel John R was granted 8,829 shares, increasing direct ownership by 2% to 368,436 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Popovits Kimberly J was granted 8,829 shares, increasing direct ownership by 31% to 37,445 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Mateo Alan was granted 8,829 shares, increasing direct ownership by 11% to 85,877 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDERDirector Kosaraju Sridhar was granted 8,829 shares, increasing direct ownership by 16% to 65,278 units (SEC Form 4)4 - 10x Genomics, Inc. (0001770787) (Issuer)
- SEC10x Genomics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - 10x Genomics, Inc. (0001770787) (Filer)
- INSIDERChief Executive Officer Saxonov Serge sold $709,057 worth of shares (28,893 units at $24.54) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 1,138,380 units (SEC Form 4) to satisfy withholding tax4 - 10x Genomics, Inc. (0001770787) (Issuer)
- INSIDEROfficer Hindson Benjamin J. sold $283,399 worth of shares (11,595 units at $24.44), decreasing direct ownership by 2% to 502,000 units (SEC Form 4) to satisfy tax liability4 - 10x Genomics, Inc. (0001770787) (Issuer)
TXG FAQ
7 questionsWhat does 10x Genomics Inc. do?
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their...Where does TXG stock trade?
10x Genomics Inc. (TXG) is listed on NASDAQ.What sector and industry is TXG in?
10x Genomics Inc. operates in the Industrials sector, Biotechnology: Laboratory Analytical Instruments industry.When did 10x Genomics Inc. go public?
10x Genomics Inc. (TXG) completed its IPO in 2019.What are analysts saying about TXG?
10x Genomics Inc. has had 8 recent analyst actions on file. The most recent action was from William Blair: Outperform on 2026-03-31. Recent price targets range from $1200.00 to $3500.00.What companies are similar to TXG?
Notable peers in the same industry include A (Agilent Technologies Inc.), WAT (Waters Corporation), MTD (Mettler-Toledo International Inc.), PKI (PerkinElmer Inc.), RVTY (Revvity Inc.). Compare TXG side-by-side with any of them on Quantisnow.How can I track TXG on Quantisnow?
Quantisnow aggregates 10x Genomics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TXG to receive live email and push alerts on every new disclosure.